The implementation of new treatment strategies based on current recommendations has enabled a greater number of patients with rheumatoid arthritis (RA) to achieve remission. However, there are no definite predictors of sustained remission. Moreover, the absence of clear consensus on the time of withdrawal or reduction of treatment further adds to the treatment burden. This pilot study was intended to evaluate the prognostic potential of various RA-related parameters. All the enrolled subjects (n=124) were clinically evaluated on the basis of various parameters including age, gender, duration of illness before the initiation of disease-modifying anti-rheumatic drugs, tender and swollen joints (28 joints), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin percentage, lymphocyte count, total white-blood cell counts, and neutrophil to lymphocyte ratio (NLR). Student's t-test and discriminant function analysis were performed. The specificity of all parameters and their best possible cut-off to predict relapse were calculated using the receiver operating characteristic (ROC) analysis. A significant difference in terms of pain perception, NLR, tendency to have a significant tender joint count and absolute lymphocyte counts was identified between the patients in sustained remission and those in relapse. The ROC analysis indicated that NLR was consistent in predicting remission. CRP, ESR, and/or disease activity score may not be very effective in differentiating patients with sustainable remission/low disease activity. NLR along with patient's perception of pain may assist in predicting sustained remission.
n INTRODUCTION R heumatoid arthritis (RA) is a chronic inflammatory disorder marked by variable cycles of remissions and relapses. In recent years, the focus on the outcome of RA has shifted significantly from symptomatic relief and reduction of erosion/ deformities to the importance of minimum disease activity and remission. This change was dictated by the evidence that the level of disease activity and the duration of remission influence the subsequent progression of the radiographic damage in RA (1) . Hence, the current recommendations have incorporated the concept of treat-to-target approach to achieve low disease activity (LDA)/remission (2) . However, there is no consensus in the recommendations about the time of withdrawal or reduction of disease-modifying anti-rheumatic drugs (DMARDs). The current treatment strategies, including early treatment with DMARDs, use of biologicals and newer DMARDs, and disease activity score (DAS)-driven treat-to-target protocols of RA increased the number of patients achieving remission (3) . Various studies indicated that a certain proportion of patients may reach remission regardless of the drugs administered to obtain disease control (4) . Several studies are currently ex- ploring whether, after achieving remission, it is necessary to continue with an intense regimen either with expensive biologics or DMARD combinations. Flare was reported in approximately 26-40% of patients depending on the number of follow-up years, the type of drugs used to induce remission, and the minimum DMARD dosage used for maintenance. These findings underscore the need for markers to predict the sustainability of remission in RA patients. The available predictors of remissions can be categorized as modifiable and nonmodifiable. The genetic make-up, patient age, and, to some extent, the delay in the initiation of the appropriate treatment are considered as non-modifiable factors. The delay in seeking medical intervention in a large cohort is modifiable through education, but it is not modifiable at the individual level once the patient sought medical attention. The modifiable factors include treatment regimen, targetable disease activity parameters, and lymphocyte count. Moreover, an effective DMARD treatment contributes to a reduction in inflammation, which is also reflected in the neutrophil to lymphocyte (NLR) ratio. DMARDs can be modified to achieve targetable outcome variables like DAS score and lymphocyte count. The changes in lymphocyte count and the ratio depend on disease activity and the influence of DMARDs on lymphocytes (5, 6) . Based on this assumption, we hypothesized that the identification of a specific treatment target for disease monitoring in the routine practice to predict sustained remission may serve as an important marker for discontinuing DMARDs. Normalization of inflammatory markers may function as an effective predictor of sustained remission, since DAS-C-reactive protein (CRP), joint count, and CRP may attain a flooring effect with a low disease activity (7). Our preliminary study suggested a weaker relationship with clinical parameters than with laboratory parameters in the presence of low disease activity (8 
n PATIENTS AND METHODS
The patients who attended our out-patient facility between March and June 2013 and fulfilled the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 classification criteria for RA were included in the study. Among these patients, those who fulfilled the remission criteria with a DAS 28 (3) CRP score below 2.6 were recruited for this study. They were evaluated at the 3 rd and 6 th month during the follow-up period within 2 weeks before and after the expected date. The following demographic and clinical characteristics were assessed at the time of recruitment: age, gender, duration of illness before the initiation of DMARD, tender (TJC) and swollen (SJC) joints (28 joints), erythrocyte sedimentation rate (ESR), CRP, hemoglobin percentage (Hb%), lymphocyte count, total whiteblood cell (WBC) counts, and NLR. The exclusion criteria considered were: noncompliance or no willingness to participate in the study, inability to comprehend the analogue scale and other tools, presence of severely deformed arthritis belonging Neutrophil-lymphocyte ratio, pain perception, and disease activity score to stage 4 Steinbrocker functional classification, and additional co-morbidities i.e. stroke, depression, fibromyalgia and overlapping connective tissue diseases, concomitant use of oral steroids and use of parenteral steroids within a month from the time of screening. Patients who required a change in the DMARD treatment due to adverse events were also excluded. The recruited patients underwent a routine assessment by a single physician. The joint evaluation was done by an independent joint assessor (IJA). Pain perception by VAS (100 mm scale), ESR (Westergren), and CRP was also determined. IJA also assisted in VAS evaluation. The study was reviewed and approved by the local Institutional ethical committee.
Statistical analysis
Student's t-test was performed using Microsoft Excel to compare the differences between the continuous variables, while the chi-square test was used for categorical variables. The remission was scored as 0 and the relapse as 1. A discriminant function analysis was carried out for all parameters using online VassarStats software. The receiver operating characteristic (ROC) analysis was performed using MedCalc to identify the specificity of all parameters and their best possible cut-off to predict relapse.
n RESULTS
Out of the 135 patients screened, 124 qualified for the study. Ten patients received parenteral or oral steroids and a screen failure was reported in 1 patient. Out of 124 patients, 110 were on oral methotrexate 15-25 mg/week, 38 on leflunomide, and 120 on hydroxychloroquine. All participants were on combination treatments and 34 were taking the three-drug combination. None had received biologicals. The Table I . Out of 124 patients, 6 were excluded, because the DMARD dosage had to be changed due to elevated liver enzymes and 30 patients missed the first follow-up visit after 3 months. Eight out of 30 patients who attended the second follow-up after 6 months attained disease remission. However, they were not considered for the study, since their first followup status was unclear. A significant difference was identified between the patients in sustained remission and in relapse with regard to pain perception, NLR, tendency to have a significant TJC, and percentage/absolute lymphocyte counts. The discriminant function analysis indicated that VAS, NLR, absolute lymphocyte count, and TJC significantly influenced the patient classification. The TJC, NLR, and VAS positively predicted relapse, while the lymphocyte count predicted it negatively (in remission). There was no significant influence of duration of disease, treatment, and age in predicting the outcome. The ROC analysis (Figure 1 ) showed that these parameters are not very strong independent predictors, since their areas under the curve (AUC) were only slightly greater than 0.5. However, CRP was found to be slightly better than NLR. The best cut-off values with a positive predictive value greater than 1.5 are indicated in Table II . Considering the ROC analysis of NLR, DAS-CRP, and CRP, NLR was found to be consistent in predicting remission. The AUC was greater for VAS, followed by CRP and NLR. However, DAS-CRP and CRP had no discriminating potential, and the positive predictive value was better for VAS followed by CRP (Table III) .
n DISCUSSION
The present study suggests that NLR, CRP, and DAS-CRP are the most effective predictors of relapse, in addition to the presence of tender joint and pain perception by the patient. The association of TJC and pain confirms the previous observations that the presence of signs of measurable inflammation is one of the important predictors of relapse. The signs of residual inflammation of RA either indicated by Power Doppler ultrasound or by the examination of TJC and VAS are negative predictors of sustained remission (17) . The discriminant function analysis as well as the difference between the remission group and the sustained remission group did not indicate the discriminating potential of SJC, DAS score, and CRP. Since SJC, CRP, and DAS-CRP are interdependent and correlated with each other, DAS-CRP can be considered as a marker representing both TJC and SJC. Moreover, TJC and SJC are included in the composite DAS score and have no discriminatory strength in the state of remission, as they are affected by a flooring effect (7).
However, the ROC analysis demonstrated that the patients in remission/relapse can Figure 1 -receiver operating characteristic curve of the six significant parameters. Crp, C-reactive protein; DaScrp, disease activity score-Crp; eSr, erythrocyte sedimentation rate; n/l, neutrophil to lymphocyte; TJC, tender joint count; VaS, visual analogue scale. Neutrophil-lymphocyte ratio, pain perception, and disease activity score be better classified by CRP than by DAS score. This is consistent in particular when CRP values are around 0.3 mg/dL. However, the likelihood ratio is very inconsistent for both higher and lower values of CRP. The ESR did not show much discriminatory predictability as shown in our previous observation that CRP overlaps and correlates with clinical disease activity better than ESR (8). Patient's perception of pain and TJC demonstrated a good discriminating strength, but TJC may not be a useful measure, as it may remain zero after remis- sion. The study results also demonstrated the usefulness of the VAS pain scale, which is a subjective assessment and one of the reliable measures of disease activity in differentiating the groups (18) . Although the measure showed consistency in discriminating the status of inflammation even at the lowest level, its reliability in the presence of fibromyalgia is a concern, as the use of analgesics/antipsychotics may alter pain perception. NLR, which demonstrated significant differences between the groups, had a better The ROC analysis of the present study suggests that DAS-CRP score below 1.6 has a greater predictive value for sustained remission and supports the concept of targeting deep remission.
n CONCLUSIONS CRP, DAS-CRP, NLR, and patient's perception of pain may serve as effective measures to predict sustained remission and low disease activity. Further research should focus on determining the optimal target values of these parameters to identify patients achieving sustained remission.
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discriminatory power compared to other markers of inflammation. The ROC analysis indicated a consistently high sensitivity and specificity. The best cut-off of NLR at which a good specificity was achievable in predicting relapse was 2.9. This is higher than the normal cut-off value of 2. Evidence in the literature supports the use of elevated NLR as a prognostic indicator in different clinical scenarios of chronic inflammation (19, 20) . Some studies suggest that it may indeed reflect disease activity in RA and other diseases. Studies of predictors of flare or failed sustained remission reported that the signs of inflammation like persisting ultrasound signs of synovitis, such as power Doppler signals of vascularity, and absence of deep remission indicate an early relapse (17, 21) . Our study confirms that the signs or laboratory parameters of inflammation are significant in predicting relapse. However, in order to decide whether to discontinue treatment, measures need to be more specific than sensitive. In this respect, NLR seems to be a good single predictor of sustained remission. However, more longterm follow-up studies are required to evaluate the usefulness of these markers and the possible complications of DMARDs withdrawal. This study was prospective, but not adequately powered due to a 20% dropout rate. Since there was no ethical committee approval for the subsequent step of DMARD withdrawal, we could not investigate whether the predictors evaluated indicate a sustainable remission even after drug discontinuation. The committee suggested we undertake such studies after proving the predictability of sustained remission. The study was carried out only for a period of 6 months, therefore our results cannot be generalized for long-term remission. Additional long-term studies characterizing NLR, CRP, and other disease parameters are required to establish the usefulness of these measures in predicting long-term remission. If confirmed, NLR may serve as a useful and cost-effective measure in predicting remission, in addition to other routine parameters. 
